Gokhan Ucar
Overview
Explore the profile of Gokhan Ucar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gurler F, Akturk Esen S, Kurt Inci B, Sutcuoglu O, Ucar G, Akdogan O, et al.
Cancer Invest
. 2024 Mar;
42(2):141-154.
PMID: 38486421
We investigated expressions of PD-L1, LAG-3, TIM-3, and OX40L as immune checkpoint proteins, and MSI (repetitive short-DNA-sequences due to defective DNA-repair system) status were analyzed with immunohistochemistry from tissue blocks....
12.
Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study
Sekmek S, Karahan I, Ucar G, Ceylan F, Bayram D, Seven I, et al.
Clin Transl Oncol
. 2024 Mar;
26(8):1878-1885.
PMID: 38451412
Aim: HER2-positive metastatic gastric cancer is still a highly fatal disease despite advances. We aimed to investigate the relationship between HER2/CEP17 ratio and survival in patients with HER2-positive metastatic gastric...
13.
Tokalioglu A, Oktar O, Sahin M, Ozturk C, Erdogan O, Yildirim H, et al.
J Obstet Gynaecol Res
. 2024 Feb;
50(4):655-662.
PMID: 38304973
Objective: The main feature of adult granulosa cell tumors (AGCT) is their capacity to secrete hormones, with nearly all of them capable of synthesizing oestradiol. The primary goal of this...
14.
Oktar O, Korkmaz V, Tokalioglu A, Ozturk C, Erdogan O, Ucar Y, et al.
J Gynecol Oncol
. 2023 Dec;
35(3):e39.
PMID: 38156722
Objective: To define the clinical, histopathological features and the prognostic factors affecting survival in patients with adult granulosa cell tumors of the ovary (AGCT). Methods: A 322 patients whose final...
15.
Sekmek S, Bayram D, Ucar G, Civelek B, Kos F, Uncu D
J Oncol Pharm Pract
. 2023 Oct;
30(1):225-227.
PMID: 37817663
Introduction: Cabozantinib is a multikinase inhibitor agent used in the treatment of hepatocellular, renal, and thyroid cancers. The development of heart failure after cabozantinib initiation is an extremely rare side...
16.
Sutcuoglu O, Dogan A, Yilmaz F, Sahin A, Sahin T, Akturk Esen S, et al.
Pancreas
. 2023 Oct;
52(4):e235-e240.
PMID: 37816170
Objective: Combination therapies such as FOLFIRINOX or gemcitabine-nanoparticle albumin-bound paclitaxel (GnP) are recommended for the first-line treatment of patients with advanced pancreatic cancer. The purpose of this study was to...
17.
Ergun Y, Dogan M, Ucar G, Karacin P, Karacin C
Expert Opin Pharmacother
. 2023 Sep;
24(17):1901-1909.
PMID: 37701962
Background: The combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and standard endocrine therapy (ET) in the adjuvant treatment of hormone receptor (HR)-positive/HER2-negative breast cancer (BC) has yielded conflicting results. We...
18.
Acikgoz Y, Yildirim F, Akturk Esen S, Ucar G, Ergun Y, Bal O, et al.
Am J Clin Oncol
. 2023 Sep;
46(12):543-550.
PMID: 37700432
Objective: We represent Sprouty 2 (Spry2) expression analysis and its association with key driver mutations and clinical features of patients with non-small cell lung cancer as the largest ex vivo...
19.
Ergun Y, Akagunduz B, Karacin C, Turker S, Ucar G
Clin Breast Cancer
. 2023 Jun;
23(6):567-575.
PMID: 37336652
This meta-analysis conducted a comprehensive analysis of research investigating the correlation between HER2 expression levels and treatment outcomes in early-stage triple-negative breast cancer (TNBC) patients. We systematically searched major databases...
20.
Bayram D, Akturk Esen S, Ucar G, Kos F
J Oncol Pharm Pract
. 2023 May;
29(6):1494-1497.
PMID: 37170613
Introduction: Hepatotoxicity is observed due to cyclin-dependent kinase (CDK4/6) inhibitors used to treat hormone receptor-positive metastatic breast cancer. However, it should not be ignored that denosumab may be hepatotoxic, although...